Denosumab

Grey

Brand Name(s):Xgeva

Indication:Skeletal-related events (prevention of) in adults with bone metastases from prostate cancer

Rationale:1

Considered:Jul-11

Review Date:Jun-23

Comments:
Drug Safety Update
Denosumab (Xgeva) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate.
June 2018
Drug Safety Update
Denosumab (Xgeva) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation
June 2018
…………………………
Drug Safety Update
Denosumab is associated with a risk of osteonecrosis of the jaw, osteonecrosis of the external auditory canal has also been reported with denosumab
June 2017